News

NICE and IQWiG nix Benlysta
Enlarge image

PolicyGermanyUK

NICE and IQWiG nix Benlysta

07.05.2012 - Healthcare cost watchdogs are not convinced by GSK’s Lupus drug Benlysta: British NICE and German IQWiG have recommended against the drug.

Cologne/London – “No additional benefit documented” – With these harsh words the German Institute for Quality and Efficiency in Health Care (IQWiG) rebuffed GSK’s Lupus antibody belimumab (Benlysta). Under the new, tougher German reimbursement regime, the Institute evaluates newly approved drugs for their additional medical benefit and issues a draft benefit assessment. That decision could mean a large, forced discount to Benlysta's price on the German market.

Although Benlysta is the first new treatment for lupus for decades, it has been slow to take off so far. Negative assessments as form NICE and IQWiG won’t help to improve the situation. GSK, Britain's biggest drugmaker, said on Thursday that the judgment from IQWiG was "completely inexplicable from a medical point of view and disregards genuine progress in therapy".

The drug was discovered by Human Genome Science (HGS) and developed jointly with GSK. In mid-April GSK offered to acquire the US-based biotech company for $2,3b. HGS’ management refused the offer, stating, it “does not reflect value inherent in company“.

„Their case for a higher bid seems to be based on the market potential of Benlysta, but the arguing has begun over how realistic those hopes are“, stated Drug discovery Chemist Derek Lowe. Besides Benlysta, HGS might bank on albiglutide (Diabetes) and darapladib (Artheroslcerosis), which are currently undergoing Phase III trials, which could bring significant revenues if approved.

http://www.european-biotechnology-news.com/news/news/2012-02/nice-and-iqwig-nix-benlysta.html

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN (D)1.75 EUR16.67%
  • SWEDISH ORPHAN BIOVITRUM (S)13.11 USD6.59%
  • RENEURON (UK)3.15 GBP5.00%

FLOP

  • VECTURA (UK)148.80 GBP-4.25%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%
  • BONE THERAPEUTICS SA (B)16.05 EUR-3.31%

TOP

  • THERAMETRICS (CH)0.05 CHF66.7%
  • PROTHENA PLC (IE)52.22 USD54.5%
  • CLINIGEN GRP (UK)675.00 GBP35.0%

FLOP

  • MOLOGEN (D)1.75 EUR-30.8%
  • EVOCUTIS (UK)0.04 GBP-20.0%
  • SANTHERA (CH)57.15 CHF-17.9%

TOP

  • KARO BIO (S)29.80 SEK1810.3%
  • NICOX (F)11.20 EUR471.4%
  • SAREUM HOLDINGS (UK)0.62 GBP169.6%

FLOP

  • BB BIOTECH (D)45.00 EUR-83.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.72 SEK-78.3%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 26.07.2016